Informatie:
Fout:
ID
16792
Beschrijving
Evaluate Quality of Life in Type 2 Diabetes, Before and After Change to Insuline Glargine; ODM derived from: https://clinicaltrials.gov/show/NCT00518427
Link
https://clinicaltrials.gov/show/NCT00518427
Trefwoorden
Versies (1)
- 07-08-16 07-08-16 -
Geüploaded op
7 augustus 2016
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Diabetes Type 2 NCT00518427
Eligibility Diabetes Type 2 NCT00518427
- StudyEvent: Eligibility
Similar models
Eligibility Diabetes Type 2 NCT00518427
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Type 2 diabetes inadequately controlled on a combination of oad + nph insulin
Item
patients with type 2 diabetes inadequately controlled on a combination of oad + nph insulin for more than three months
boolean
C0011860 (UMLS CUI [1])
C0860160 (UMLS CUI [2,1])
C0021658 (UMLS CUI [2,2])
C0860160 (UMLS CUI [3,1])
C0359086 (UMLS CUI [3,2])
C0860160 (UMLS CUI [2,1])
C0021658 (UMLS CUI [2,2])
C0860160 (UMLS CUI [3,1])
C0359086 (UMLS CUI [3,2])
Stable oad therapy
Item
stable oad therapy for at least three months, according to the following specified daily dose: glibenclamide> 3, 5 mg, glipizid >5 mg, glimepiride >2mg, metformin>1000 mg, acarbose >150 mg
boolean
C0017628 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0017642 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0061323 (UMLS CUI [3,1])
C0178602 (UMLS CUI [3,2])
C0025598 (UMLS CUI [4,1])
C0178602 (UMLS CUI [4,2])
C0050393 (UMLS CUI [5,1])
C0178602 (UMLS CUI [5,2])
C0178602 (UMLS CUI [1,2])
C0017642 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0061323 (UMLS CUI [3,1])
C0178602 (UMLS CUI [3,2])
C0025598 (UMLS CUI [4,1])
C0178602 (UMLS CUI [4,2])
C0050393 (UMLS CUI [5,1])
C0178602 (UMLS CUI [5,2])
HbA1C
Item
hba1c > 7,0%
boolean
C0202054 (UMLS CUI [1])
ability to perform qol assessment
Item
ability to perform qol assessment
boolean
C1321605 (UMLS CUI [1,1])
C0281588 (UMLS CUI [1,2])
C0281588 (UMLS CUI [1,2])
BMI
Item
body mass indes: women <30 and men <32
boolean
C1305855 (UMLS CUI [1])
Autoimmune diabetes
Item
autoimmune diabetes, as defined by who
boolean
C0205734 (UMLS CUI [1])
Thiazolidinedione
Item
ongoing treatment with thiazolidinedione drug
boolean
C1257987 (UMLS CUI [1])
Retinopathy with surgical treatment
Item
retinopathy with surgical treatment during preceding three months of study entry or requiring treatment within three months after study entry
boolean
C0011884 (UMLS CUI [1,1])
C0543467 (UMLS CUI [1,2])
C0543467 (UMLS CUI [1,2])
Drug abuse
Item
drug abuse
boolean
C0038586 (UMLS CUI [1])
hypersensitivity to insulin glagine excipients
Item
hypersensitivity to insulin glagine excipients
boolean
C0020517 (UMLS CUI [1,1])
C0907402 (UMLS CUI [1,2])
C0907402 (UMLS CUI [1,2])
Study Subject Participation Status
Item
the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
boolean
C2348568 (UMLS CUI [1])